Biogen Inc

Market Summary

USD239.29+0.17

Market Closed

0.07%

BIIB Alerts

Big fall in earnings (Y/Y)
Losses in recent quarter

BIIB Stock Price

View Fullscreen

BIIB RSI Chart

BIIB Alerts

Big fall in earnings (Y/Y)
Losses in recent quarter

BIIB Valuation

Market Cap

34.6B

Price/Earnings (Trailing)

23.69

Price/Sales (Trailing)

3.46

EV/EBITDA

16.91

Price/Free Cashflow

32.62

BIIB Price/Sales (Trailing)

BIIB Profitability

EBT Margin

16.10%

Return on Equity

10.1%

Return on Assets

5.18%

Free Cashflow Yield

3.07%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

10.0B

Revenue Y/Y

0.87%

Revenue Q/Q

3.03%

BIIB Earnings

Earnings (TTM)

1.5B

Earnings Y/Y

-106%

Earnings Q/Q

-111.51%

Price Action

Last 7 days

2.0%

Last 30 days

3.3%

Last 90 days

-7.6%

Trailing 12 Months

-17.2%

How does BIIB drawdown profile look like?

BIIB Financial Health

Current Ratio

1.68

Debt/Equity

0.47

Debt/Cashflow

0.2

BIIB Investor Care

Buy Backs (1Y)

0.82%

Diluted EPS (TTM)

10.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	10.1B	10.0B	10.0B	0
2022	10.8B	10.6B	10.4B	10.2B
2021	12.6B	11.7B	11.1B	11.0B
2020	14.4B	14.5B	14.3B	13.4B
2019	13.8B	14.1B	14.2B	14.4B
2018	12.6B	12.9B	13.2B	13.5B
2017	11.5B	11.7B	11.8B	12.3B
2016	10.9B	11.2B	11.4B	11.4B
2015	10.1B	10.3B	10.6B	10.8B
2014	7.6B	8.3B	9.0B	9.7B
2013	5.6B	5.9B	6.4B	6.9B
2012	5.1B	5.3B	5.4B	5.5B
2011	4.8B	4.8B	4.9B	5.0B
2010	4.4B	4.6B	4.6B	4.7B
2009	4.2B	4.3B	4.3B	4.4B
2008	3.4B	3.6B	3.9B	4.1B
2007	0	0	0	3.2B

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for BIIB

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 05, 2023	singhal priya	sold	-116,124	269	-431	head of development
Sep 01, 2023	singhal priya	sold (taxes)	-215,606	267	-807	head of development
Sep 01, 2023	mcdonnell michael r	acquired	-	-	5,285	evp, chief financial officer
Sep 01, 2023	singhal priya	acquired	-	-	1,668	head of development
Sep 01, 2023	mcdonnell michael r	sold (taxes)	-722,428	267	-2,704	evp, chief financial officer
Jul 03, 2023	singhal priya	sold	-22,912	282	-81.00	head of development
Jun 30, 2023	singhal priya	acquired	-	-	315	head of development
Jun 30, 2023	kramer robin	acquired	-	-	252	chief accounting officer
Jun 30, 2023	izzar rachid	acquired	-	-	504	head of global product strat.
Jun 30, 2023	izzar rachid	sold (taxes)	-69,503	284	-244	head of global product strat.

Which funds bought or sold BIIB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 07, 2023	Hudson Bay Capital Management LP	added	186	26,027,800	42,406,600	0.17%
Dec 06, 2023	Raleigh Capital Management Inc.	unchanged	-	-696	6,425	-%
Dec 06, 2023	CITIGROUP INC	reduced	-5.6	-9,917,810	56,994,000	0.04%
Dec 04, 2023	Phoenix Holdings Ltd.	sold off	-100	-617,772	-	-%
Dec 04, 2023	Trust Co	unchanged	-	-4,538	41,893	0.01%
Dec 01, 2023	B. Riley Wealth Advisors, Inc.	reduced	-9.08	-195,587	893,110	0.02%
Dec 01, 2023	Fortis Group Advisors, LLC	new	-	3,855	3,855	-%
Nov 29, 2023	Carmignac Gestion	reduced	-0.32	-8,888,660	79,442,000	1.46%
Nov 27, 2023	USA FINANCIAL FORMULAS	added	0.45	-227,097	2,196,410	3.28%
Nov 27, 2023	BANQUE PICTET & CIE SA	reduced	-38.99	-5,042,360	6,173,890	0.07%

Latest Funds Activity

Are funds buying BIIB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIIB

No. of Funds

Schedule 13G FIlings of Biogen Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	8.32%	11,976,623	SC 13G/A
Feb 09, 2023	primecap management co/ca/	10.9%	15,700,576	SC 13G/A
Jan 24, 2023	blackrock inc.	9.9%	14,260,137	SC 13G/A
Mar 07, 2022	blackrock inc.	9.4%	13,736,954	SC 13G/A
Feb 10, 2022	primecap management co/ca/	10.73%	15,757,405	SC 13G/A
Feb 09, 2022	vanguard group inc	7.85%	11,537,299	SC 13G/A
Feb 08, 2022	blackrock inc.	9.4%	13,736,954	SC 13G
Feb 12, 2021	primecap management co/ca/	10.28%	15,822,066	SC 13G/A
Feb 10, 2021	vanguard group inc	7.73%	11,896,510	SC 13G/A
Jan 29, 2021	blackrock inc.	8.7%	13,419,601	SC 13G/A

Recent SEC filings of Biogen Inc

View All Filings

Date Filed	Form Type	Document
Nov 08, 2023	8-K	Current Report
Nov 08, 2023	8-K	Current Report
Nov 08, 2023	10-Q	Quarterly Report
Nov 03, 2023	4	Insider Trading
Oct 12, 2023	3	Insider Trading
Sep 28, 2023	SC 13D/A	13D - Major Acquisition
Sep 28, 2023	8-K/A	Current Report
Sep 28, 2023	4	Insider Trading
Sep 26, 2023	8-K	Current Report
Sep 06, 2023	4	Insider Trading

BIIB Fair Value

Peers (Alternatives to Biogen Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	389.5B	102.8B	2.69%	-12.25%	11.25	3.79	11.47%	80.74%
MRK	272.8B	59.3B	-0.63%	-5.14%	17.88	4.63	0.58%	-69.80%
PFE	162.5B	68.5B	-6.62%	-44.42%	15.5	2.37	-31.38%	-64.79%
AMGN	144.0B	26.8B	-1.52%	-4.93%	19.03	5.37	1.91%	10.69%
GILD	98.5B	27.4B	1.44%	-10.10%	16.77	3.6	0.94%	76.21%
MID-CAP
TEVA	11.0B	15.3B	7.32%	18.03%	-4.98	0.72	0.87%	-71.24%
ALKS	4.3B	1.6B	4.36%	1.49%	20.08	2.71	40.56%	266.27%
PRGO	4.0B	4.7B	2.10%	-7.72%	-978.12	0.86	5.74%	96.18%
AMPH	2.7B	601.3M	24.99%	94.42%	20.1	4.52	24.02%	75.17%
BHC	2.7B	8.5B	1.81%	-4.07%	-2.77	0.31	5.11%	-479.13%
SMALL-CAP
TLRY	1.4B	650.9M	10.34%	-28.86%	-0.96	2.13	6.08%	-185.21%
TXMD	22.1M	-	-5.00%	-65.05%	0.32	0.55	-19.54%	888.31%
ACOR	15.2M	111.1M	27.41%	2089.90%	-0.96	0.14	-10.43%	84.90%
ACRX	12.5M	-	39.62%	-61.05%	-0.59	0.13	287.27%	-145.15%
AGRX	5.2M	20.0M	16.16%	1110.53%	-0.38	0.26	137.71%	66.04%

Biogen Inc News

Latest updates

Defense World • 09 Dec 2023 • 08:23 am • 19 hours ago

Research Analysts Set Expectations for Biogen Inc.'s FY2024 ...

StockNews.com • 08 Dec 2023 • 04:41 pm • 34 hours ago

GILD: GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Nasdaq • 08 Dec 2023 • 04:30 pm • 34 hours ago

Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?

MarketBeat • 08 Dec 2023 • 01:19 pm • 38 hours ago

State Street Corp Has $1.96 Billion Position in Biogen Inc. (NASDAQ ...

MarketBeat • 08 Dec 2023 • 11:25 am • 40 hours ago

FY2023 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Boosted by ...

London South East • 06 Dec 2023 • 11:31 pm • 3 days ago

US close: Stocks extend losses another session | Financial News

Yahoo Finance • 30 Nov 2023 • 08:00 am • 9 days ago

Are Biogen Inc.'s (NASDAQ:BIIB) Mixed Financials The Reason For ...

Nasdaq • 27 Nov 2023 • 08:00 am • 12 days ago

Validea Detailed Fundamental Analysis - BIIB

MarketBeat • 21 Nov 2023 • 08:00 am • 18 days ago

Employees Retirement System of Texas Buys 35000 Shares of ...

Yahoo Finance • 17 Nov 2023 • 08:00 am • 22 days ago

The past five years for Biogen (NASDAQ:BIIB) investors has not ...

MarketWatch • 15 Nov 2023 • 09:59 pm • 24 days ago

Biogen Inc. stock outperforms market on strong trading day

Insider Monkey • 14 Nov 2023 • 02:49 am • 26 days ago

Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks

Simply Wall St • 10 Nov 2023 • 08:00 am • 29 days ago

Investors five-year losses continue as Biogen (NASDAQ:BIIB) dips a further 7.1% this week, earnings continue to decline

Bloomberg • 08 Nov 2023 • 08:00 am • 31 days ago

Biogen Lowers 2023 Earnings Guidance on Costs of Reata Purchase

Nasdaq • 08 Nov 2023 • 08:00 am • 31 days ago

Biogen Inc. Q3 Earnings Summary

Financials for Biogen Inc

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	3.0%	2,530	2,456	2,463	2,544	2,509	2,589	2,532	2,734	2,779	2,775	2,694	2,853	3,376	3,682	3,534	3,671	3,600	3,617	3,490	3,526	3,439
Costs and Expenses	52.8%	2,672	1,748	2,025	1,940	1,137	1,320	2,184	2,582	2,488	2,193	1,720	2,686	2,290	1,707	1,714	1,894	1,794	1,661	1,987	2,083	1,741
S&GA Expenses	43.8%	788	548	605	633	563	573	635	788	654	637	595	806	573	555	570	665	555	588	568	591	498
EBITDA Margin	-39.5%	0.23*	0.38*	0.44*	0.43*	0.40*	0.29*	0.22*	0.23*	-	-	0.36*	0.43*	0.48*	0.54*	0.53*	0.54*	0.56*	-	-	-	-
Interest Expenses	29.9%	64.00	49.00	63.00	55.00	60.00	66.00	66.00	66.00	66.00	56.00	65.00	56.00	56.00	66.00	44.00	46.00	46.00	48.00	48.00	49.00	49.00
Income Taxes	-163.5%	-72.90	115	51.00	54.00	236	217	126	443	-25.90	-409	44.00	13.00	241	446	292	276	211	248	423	470	370
Earnings Before Taxes	-119.9%	-141	708	438	604	1,371	1,270	347	405	291	582	467	353	958	2,038	1,699	1,728	1,779	1,759	1,860	1,415	1,813
EBT Margin	-48.6%	0.16*	0.31*	0.36*	0.35*	0.33*	0.22*	0.15*	0.16*	0.15*	0.20*	0.30*	0.38*	0.45*	0.50*	0.48*	-	-	-	-	-	-
Net Income	-111.5%	-68.10	592	388	550	1,135	1,058	304	368	329	449	410	358	702	1,542	1,399	1,440	1,546	1,494	1,409	947	1,444
Net Income Margin	-45.3%	0.15*	0.27*	0.31*	0.30*	0.28*	0.19*	0.13*	0.14*	0.14*	0.16*	0.24*	0.30*	0.36*	0.41*	0.41*	-	-	-	-	-	-
Free Cashflow	24.6%	518	416	389	-261	602	700	104	787	763	1,155	676	-453	1,097	1,844	1,318	-	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	12.1%	28,193	25,157	24,598	24,554	24,854	25,081	23,614	23,877	23,807	24,470	23,855	24,619	24,934	25,512	26,119	27,234	27,484	26,288	26,446	25,289	25,492
Current Assets	-19.0%	8,454	10,432	9,763	9,791	9,766	9,741	7,916	7,857	7,162	7,184	6,720	6,887	7,843	8,494	8,007	8,382	8,448	7,910	8,943	7,641	8,719
Cash Equivalents	-12.6%	2,288	2,618	2,898	3,419	3,676	2,647	1,749	2,261	1,542	1,742	1,218	1,331	2,225	2,385	2,591	2,914	2,344	1,723	2,243	1,225	2,387
Inventory	123.7%	2,982	1,334	1,281	1,344	1,375	1,294	1,215	1,352	1,348	1,255	1,172	1,069	1,028	953	859	804	752	777	770	930	917
Net PPE	-0.2%	3,302	3,307	3,301	3,299	3,266	3,355	3,373	3,416	3,411	3,442	3,438	3,412	3,360	3,331	3,282	3,247	3,138	3,078	3,014	3,601	3,539
Goodwill	18.3%	6,808	5,754	5,752	5,749	5,741	5,750	5,758	5,761	5,761	5,764	5,763	5,762	5,756	5,751	5,752	5,758	5,746	5,749	5,640	5,706	5,440
Liabilities	28.2%	13,714	10,696	10,811	11,166	12,087	13,218	12,394	12,918	12,925	13,256	13,192	13,933	14,190	14,223	13,582	13,895	13,492	13,339	12,624	12,257	11,732
Current Liabilities	57.6%	5,022	3,187	3,015	3,273	3,926	5,018	3,947	4,298	4,212	3,347	3,166	3,742	3,804	3,447	4,639	4,864	4,432	3,211	3,149	3,295	3,175
Long Term Debt	8.0%	6,786	6,285	6,283	6,281	6,279	6,277	6,276	6,274	6,272	7,269	7,267	7,426	7,425	7,424	4,460	4,459	4,458	5,949	5,943	5,937	5,931
Shareholder's Equity	0.1%	14,480	14,467	13,787	13,398	12,776	11,863	11,221	10,960	10,882	11,215	10,663	10,686	10,745	11,289	12,537	13,339	13,992	12,949	13,822	13,032	13,767
Retained Earnings	-0.4%	17,378	17,446	16,854	16,467	15,916	14,960	14,216	13,912	13,544	13,901	13,834	13,976	13,961	14,467	15,673	16,455	17,065	16,183	17,027	16,257	16,944
Additional Paid-In Capital	41.9%	242	171	91.00	73.00	-	-	119	68.00	-	-	-	-	-	-	0.00	-	-	-	-	-	48.00
Shares Outstanding	-100.0%	-	145	144	-	144	146	147	-	148	150	152	154	157	161	173	178	184	190	197	200	201
Minority Interest	35.9%	-4.10	-6.40	-9.60	-9.50	-8.70	-9.10	-21.60	64.00	452	463	-19.00	-14.20	-14.00	-19.50	-10.00	-4.10	-4.10	-4.10	-7.90	-8.00	-6.80

Cashflow (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	21.6%	592	487	455	-175	661	737	162	838	805	1,227	769	-367	1,181	1,949	1,467	1,960	1,695	1,964	1,460	1,895	1,736
Share Based Compensation	12.6%	-64.80	-74.10	76.00	189	-65.70	-58.00	68.00	170	-57.60	-55.80	70.00	132	-35.40	-49.50	68.00	139	-47.80	-55.00	46.00	35.00	40.00
Cashflow From Investing	-131.2%	-1,742	-753	-953	-141	1,672	694	-648	-112	-233	-152	-64.70	-166	-52.40	-832	443	708	-365	-110	239	-1,625	-619
Cashflow From Financing	8759.2%	849	-9.80	-43.40	-7.40	-1,251	-471	-16.50	10.00	-746	-564	-785	-401	-1,312	-1,313	-2,245	-2,116	-689	-2,375	-679	-1,437	25.00
Buy Backs	-	-	-	-	-	250	500	-	-	750	450	600	400	1,250	2,809	2,220	2,093	718	2,402	656	1,353	-

BIIB Income Statement

2023-09-30

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total revenue	$ 2,530.3	$ 2,508.5	$ 7,449.3	$ 7,629.4
Cost and expenses:
Cost of sales, excluding amortization and impairment of acquired intangible assets	659.6	469.5	1,915.1	1,707.4
Research and development	736.3	549.2	1,891.1	1,629.5
Selling, general and administrative	788.2	563.3	1,941.2	1,770.8
Amortization and impairment of acquired intangible assets	60.9	56.5	164.0	190.9
Collaboration profit sharing/(loss reimbursement)	50.5	45.3	164.5	(42.6)
(Gain) loss on fair value remeasurement of contingent consideration	0.0	(2.1)	0.0	(13.7)
Restructuring charges	76.0	15.4	120.0	124.1
Gain on sale of building	0.0	503.7	0.0	503.7
Other (income) expense, net	300.0	(56.0)	248.2	(221.3)
Total cost and expense	2,671.5	1,137.4	6,444.1	4,641.4
Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax	(141.2)	1,371.1	1,005.2	2,988.0
Income tax (benefit) expense	(72.9)	236.2	92.6	578.5
Equity in (income) loss of investee, net of tax	0.0	0.0	0.0	(2.6)
Net income (loss)	(68.3)	1,134.9	912.6	2,412.1
Net income (loss) attributable to noncontrolling interests, net of tax	(0.2)	0.2	1.2	(84.4)
Net income (loss) attributable to Biogen Inc.	$ (68.1)	$ 1,134.7	$ 911.4	$ 2,496.5
Net income per share:
Basic earnings (loss) per share attributable to Biogen Inc.	$ (0.47)	$ 7.86	$ 6.30	$ 17.12
Diluted earnings (loss) per share attributable to Biogen Inc.	$ (0.47)	$ 7.84	$ 6.26	$ 17.07
Weighted-average shares used in calculating:
Basic earnings (loss) per share attributable to Biogen Inc.	144,800	144,400	144,700	145,800
Diluted earnings (loss) per share attributable to Biogen Inc.	144,800	144,800	145,500	146,200
Product, net
Total revenue	$ 1,805.2	$ 1,962.1	$ 5,414.3	$ 6,083.3
LEQEMBI Collaboration
Cost and expenses:
Selling, general and administrative	38.7
Revenue from anti-CD20 therapeutic programs
Total revenue	420.9	416.9	1,253.8	1,252.6
Contract manufacturing, royalty and other revenue
Total revenue	$ 304.2	$ 129.5	$ 781.2	$ 293.5

BIIB Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,287.9	$ 3,419.3
Marketable securities	0.0	1,473.5
Inventory	2,982.4	1,344.4
Other current assets	974.1	1,417.6
Total current assets	8,454.1	9,791.2
Marketable securities	0.1	705.7
Property, plant and equipment, net	3,301.6	3,298.6
Operating lease assets	460.9	403.9
Intangible assets, net	7,344.6	1,850.1
Goodwill	6,807.5	5,749.0
Deferred tax asset	1,069.8	1,226.4
Investments and other assets	754.6	1,529.2
Total assets	28,193.2	24,554.1
Current liabilities:
Current portion of term loan	500.0	0.0
Taxes payable	243.8	259.9
Accounts payable	440.1	491.5
Accrued expense and other	3,838.4	2,521.4
Total current liabilities	5,022.3	3,272.8
Notes payable and term loan	6,786.4	6,281.0
Deferred tax liability	728.1	334.7
Long-term operating lease liabilities	428.8	333.0
Other long-term liabilities	747.9	944.2
Total liabilities	13,713.5	11,165.7
Commitments, contingencies and guarantees
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	242.2	73.3
Accumulated other comprehensive income (loss)	(159.3)	(164.9)
Retained earnings	17,377.9	16,466.5
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	14,483.8	13,397.9
Noncontrolling interests	(4.1)	(9.5)
Total equity	14,479.7	13,388.4
Total liabilities and equity	28,193.2	24,554.1
Nonrelated Party
Current assets:
Accounts receivable, net	1,781.4	1,705.0
Related Party
Current assets:
Accounts receivable, net	$ 428.3	$ 431.4

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Christopher A. Viehbacher
WEBSITE	www.biogen.com
EMPLOYEES	8725

Biogen Inc Frequently Asked Questions

What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Fri Dec 08 2023, market cap of Biogen Inc is 34.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart. The fair value of Biogen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biogen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, BIIB's PE ratio (Price to Earnings) is 23.69 and Price to Sales (PS) ratio is 3.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.009 (multiply by 100 for percentage) rate of return.

Market Summary

BIIB Alerts

BIIB Stock Price

BIIB RSI Chart

BIIB Alerts

BIIB Valuation

BIIB Price/Sales (Trailing)

BIIB Profitability

BIIB Fundamentals

BIIB Revenue

BIIB Earnings

Price Action

How does BIIB drawdown profile look like?

BIIB Financial Health

BIIB Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for BIIB

Which funds bought or sold BIIB recently?

Latest Funds Activity

Schedule 13G FIlings of Biogen Inc

Recent SEC filings of Biogen Inc

BIIB Fair Value

Peers (Alternatives to Biogen Inc)

Biogen Inc News

Financials for Biogen Inc

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

BIIB Income Statement

BIIB Balance Sheet

About Biogen Inc

Biogen Inc Frequently Asked Questions

What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

What is the market capital of Biogen Inc (BIIB)?

What is the fair value of BIIB stock?

Is Biogen Inc a good stock to buy?

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

What is 5 year return on Biogen Inc's stock?

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)